Abstract
<p>Linezolid is approved for complicated and uncomplicated skin and soft tissue infections. We have evaluated the efficacy of this drug in murine as well as in rat skin and soft tissue infection models using <em>Staphylococcus aureus</em> ATCC and clinical strains. In thigh infection model the dose of linezolid required for more than 1 log<sub>10</sub> kill from baseline inoculum in neutropenic mice and rats was 100 mg/kg and 50 mg/Kg BW bid /day, respectively, which was 5 and 4 folds more than that in immunocompetent animals, respectively. Dose required to achieve 1 log<sub>10</sub> killing was similar against different strains of <em>S. aureus </em>in immunocompetent mouse thigh infection model. However, in murine groin abscess infection model, a dose of 100 mg/kg, b.i.d/day of linezolid produce static effect in 2 days, but revealed to be superior in 4 days treatment and showed approximately 1 log<sub>10</sub> killing from base line inoculums. Based upon pharmacokinetic profile, a 24-h AUC/MIC required for linezolid efficacy in murine groin abscess model was 91.5 for the strain used in this study. As linezolid is taken as a gold standard drug in the evaluation of new chemical entity, this data could be useful for comparing the preclinical efficacy of new anti-MRSA agents.</p>
Highlights
Staphylococcus aureus, once largely suscep- Drug preparationLinezolid was procured from the National Chemical Laboratory (Pune, India)
In murine SSTI aureus strains used in this study is presented model, all tested S. aureus strains showed good
Complicated skin and soft tissue infections caused by S. aureus are frequently encountered in clinical practice and are the significant cause of morbidity and mortality in hospitalized patients
Summary
The objective of the present study is to evaluate and compare the efficacy of linezolid against various S. aureus strains in an immunocompetent and neutropenic mouse as well as rat thigh infection models and in murine groin abscess model, which is a more complicated skin and soft tissue infection model
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
